PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.82%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-4.34%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-6.85%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-6.85%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
4.17%
D&A growth less than half of TRVN's 88.07%. David Dodd would verify if efficiency is sustainable.
16.91%
Similar EBITDA growth to TRVN's 16.60%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Similar operating income growth to TRVN's 17.11%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
-5.45%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
16.61%
Similar pre-tax income growth to TRVN's 17.09%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while TRVN shows 123.00% growth. Joel Greenblatt would examine advantage.
16.61%
Similar net income growth to TRVN's 17.09%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
17.14%
Similar EPS growth to TRVN's 18.62%. Walter Schloss would investigate industry trends.
17.14%
Similar diluted EPS growth to TRVN's 18.62%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.